AVA vs CTRI

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score limits distress risk assessment. AVA trades near its analyst target price of $41.00 and slightly below the growth-based intrinsic value of $69.62, but well above the conservative Graham Number of $41.55. Strong recent earnings growth (YoY +56.4%) and a high dividend yield (4.83%) are offset by declining earnings estimate accuracy, insider selling, and weak technical momentum. Relative to sector peers, AVA has below-average revenue growth and profitability but a more stable payout and moderate leverage.

CTRI exhibits a strong deterministic health profile with a Piotroski F-Score of 8/9, indicating robust operational improvements. However, this fundamental health is completely decoupled from its market valuation, with the current price of $34.74 trading at a massive premium to both the Graham Number ($6.98) and Intrinsic Value ($7.38). Despite explosive YoY earnings growth, the company has missed analyst estimates in four consecutive quarters, and the current P/E of 138.96 is unsustainable. The stock is currently trading at its 52-week high while analyst target prices ($31.34) have already fallen below the current market price.